Abstract
The PI3K–AKT–mTOR pathway has long been an attractive oncology target. But with top-line results from the most advanced AKT inhibitor due soon, many questions remain over which targets to hit and how to combine agents.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
